Publication Date:
2016-07-29
Description:
Article CAR-T targeting CD19 have been successfully used in a variety of B-cell malignancies but patients may eventually relapse. Here, the authors show that CD19 CAR-T resistance in pre-B cell ALL can be due to the induction of a myeloid lineage switch through an epigenetic alterations in master regulators of B cell development. Nature Communications doi: 10.1038/ncomms12320 Authors: Elad Jacoby, Sang M. Nguyen, Thomas J. Fountaine, Kathryn Welp, Berkley Gryder, Haiying Qin, Yinmeng Yang, Christopher D. Chien, Alix E. Seif, Haiyan Lei, Young K. Song, Javed Khan, Daniel W. Lee, Crystal L. Mackall, Rebecca A. Gardner, Michael C. Jensen, Jack F. Shern, Terry J. Fry
Electronic ISSN:
2041-1723
Topics:
Biology
,
Chemistry and Pharmacology
,
Natural Sciences in General
,
Physics
Permalink